Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer

KRAS and TP53 mutations, which are the most common genetic drivers of tumorigenesis, are still considered undruggable targets. Therefore, we analyzed these genetic aberrations in metastatic non-small cell lung cancer (NSCLC) for the development of potential therapeutics. One hundred eighty-five cons...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yudong, Wang, Zhijie, Piha-Paul, Sarina, Janku, Filip, Subbiah, Vivek, Shi, Naiyi, Hess, Kenneth, Broaddus, Russell, Shan, Baoen, Naing, Aung, Hong, David, Tsimberidou, Apostolia M., Karp, Daniel, Lu, Charles, Papadimitrakopoulou, Vali, Heymach, John, Meric-Bernstam, Funda, Fu, Siqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161801/
https://www.ncbi.nlm.nih.gov/pubmed/30279957
http://dx.doi.org/10.18632/oncotarget.25947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161801/
https://www.ncbi.nlm.nih.gov/pubmed/30279957
http://dx.doi.org/10.18632/oncotarget.25947

Ejemplares similares